Your browser is no longer supported. Please, upgrade your browser.
Settings
GRTS Gritstone Oncology, Inc. daily Stock Chart
GRTS [NASD]
Gritstone Oncology, Inc.
Index- P/E- EPS (ttm)-2.61 Insider Own7.27% Shs Outstand33.17M Perf Week24.80%
Market Cap360.56M Forward P/E- EPS next Y-2.58 Insider Trans0.00% Shs Float32.15M Perf Month39.36%
Income-84.10M PEG- EPS next Q-0.69 Inst Own78.30% Short Float9.88% Perf Quarter-0.73%
Sales4.60M P/S78.38 EPS this Y-51.40% Inst Trans-0.09% Short Ratio28.51 Perf Half Y12.64%
Book/sh4.38 P/B2.48 EPS next Y2.60% ROA-41.90% Target Price22.00 Perf Year-58.37%
Cash/sh4.50 P/C2.41 EPS next 5Y- ROE-54.20% 52W Range7.00 - 29.67 Perf YTD-29.64%
Dividend- P/FCF- EPS past 5Y- ROI-41.10% 52W High-63.36% Beta-
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low55.29% ATR0.69
Employees164 Current Ratio6.80 Sales Q/Q900.00% Oper. Margin- RSI (14)73.73 Volatility9.54% 8.27%
OptionableNo Debt/Eq0.00 EPS Q/Q-20.60% Profit Margin- Rel Volume2.80 Prev Close9.21
ShortableYes LT Debt/Eq0.00 EarningsNov 13 Payout- Avg Volume111.40K Price10.87
Recom1.90 SMA2032.05% SMA5033.10% SMA2006.05% Volume311,854 Change18.02%
Jul-26-19Initiated Robert W. Baird Outperform $17
Mar-15-19Initiated Raymond James Outperform
Mar-07-19Initiated H.C. Wainwright Buy $17
Oct-23-18Initiated Goldman Neutral $18
Oct-23-18Initiated BTIG Research Buy $26
Dec-09-19 08:00AM  Gritstone Oncology to Webcast a Review of the Clinical Immunogenicity Data from its Neoantigen-based Immunotherapies that will be Presented at the ESMO Immuno-Oncology Congress GlobeNewswire
Nov-26-19 08:00AM  Gritstone Oncology to Present at the Piper Jaffray Annual Healthcare Conference GlobeNewswire -5.33%
Nov-12-19 10:15AM  Gritstone Oncology, Inc. (GRTS) Reports Q3 Loss, Misses Revenue Estimates Zacks
09:01AM  Gritstone Oncology Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Nov-06-19 10:30AM  Will Gritstone Oncology, Inc. (GRTS) Report Negative Q3 Earnings? What You Should Know Zacks
Nov-05-19 08:05AM  Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE Platform and Contained Within its SLATE Immunotherapy GlobeNewswire
Oct-31-19 08:00AM  Gritstone Oncology to Webcast Investor Event Reviewing its Neoantigen-based Immunotherapies During SITC Conference GlobeNewswire +5.87%
Oct-07-19 08:00AM  Gritstone Oncology Announces Upcoming Presentation on Novel Shared Neoantigens Included within Off-The-Shelf SLATE Immunotherapy at SITC 2019 Annual Meeting GlobeNewswire
Sep-27-19 08:22AM  Investors Who Bought Gritstone Oncology (NASDAQ:GRTS) Shares A Year Ago Are Now Down 37% Simply Wall St. -5.59%
Sep-26-19 08:00AM  Gritstone Oncology to Present at Cantor Global Healthcare Conference GlobeNewswire
Sep-12-19 08:00AM  Gritstone Oncology Announces Changes to its Board of Directors, Including the Appointment of Biotech Veteran Dr. Elaine V. Jones GlobeNewswire -6.85%
Aug-14-19 03:40PM  Its not just Bloom Energy: Half of last years Bay Area IPO stocks are underwater American City Business Journals
08:00AM  Gritstone Oncology Announces First Patient Dosed with SLATE, its Off-The-Shelf Neoantigen Immunotherapy GlobeNewswire
Aug-12-19 09:01AM  Gritstone Oncology Reports Second Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Jul-08-19 08:00AM  Gritstone Oncology Announces the Appointment of Dr. Vijay Yabannavar, a Biopharma Leader with Over 30 Years of Experience, as Executive Vice President of Manufacturing and Technical Operations GlobeNewswire
Jun-05-19 08:00AM  Gritstone Oncology to Present at Two Upcoming Investor Conferences in June GlobeNewswire
Jun-03-19 11:00AM  Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO American City Business Journals
May-30-19 08:00AM  Gritstone Oncology to Host Event with Oncology Key Opinion Leaders Discussing Neoantigen-based Immunotherapy During ASCO Annual Meeting GlobeNewswire
May-27-19 07:39AM  Could Gritstone Oncology, Inc.'s (NASDAQ:GRTS) Investor Composition Influence The Stock Price? Simply Wall St.
May-13-19 09:01AM  Gritstone Oncology Reports First Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
May-09-19 08:56PM  Heres What Hedge Funds Think About Gritstone Oncology, Inc. (GRTS) Insider Monkey
Apr-25-19 11:42AM  Why Gritstone Oncology Stock Is Sinking Today Motley Fool -12.93%
07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
Apr-24-19 08:53PM  Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock GlobeNewswire -5.02%
Apr-23-19 08:08AM  The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale Benzinga -11.00%
Apr-22-19 04:28PM  Gritstone Oncology Announces Proposed Public Offering of Common Stock GlobeNewswire +5.90%
08:00AM  Gritstone Oncology Announces Clinical Acceleration of Off-The-Shelf Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback GlobeNewswire
Apr-04-19 08:00AM  Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board GlobeNewswire +5.13%
Apr-03-19 04:00PM  Gritstone Oncology to Present at Needham Healthcare Conference GlobeNewswire
10:02AM  After inking lease with cancer-fighting company, this new East Bay biotech project is full American City Business Journals
Apr-02-19 04:00PM  Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE Significantly Outperforms Current Prediction Methods GlobeNewswire +9.51%
Mar-28-19 04:00PM  Gritstone Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights GlobeNewswire +5.47%
Mar-25-19 09:19AM  Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals
Mar-21-19 04:00PM  Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001 GlobeNewswire
Mar-11-19 08:00AM  Gritstone Oncology Announces the Appointment of Technology Executive, Mike Forcht, as Senior Vice President of Human Resources to Support Vision for Growth GlobeNewswire
Mar-05-19 04:00PM  Gritstone Oncology to Present at Two Upcoming Investor Conferences in March GlobeNewswire -8.10%
Feb-27-19 06:12PM  Gritstone Oncology Announces Oral Presentation on MHC Class II Antigen Prediction at the AACR Annual Meeting in April 2019 GlobeNewswire
Feb-20-19 04:00PM  Gritstone Oncology to Present at Leerink Partners Annual Global Healthcare Conference GlobeNewswire
Jan-06-19 08:00AM  Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-19 06:16PM  Gritstone Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-18 10:11AM  2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma American City Business Journals
Dec-20-18 04:00PM  Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer GlobeNewswire -17.00%
Dec-19-18 04:17PM  TCR2 Therapeutics Announces Oncology Industry Leader and Expert Andrew Allen, M.D., Ph.D. Joins its Board of Directors PR Newswire -9.32%
Dec-17-18 11:00AM  Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE GlobeNewswire -7.08%
Dec-15-18 08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-10-18 07:00AM  Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead GlobeNewswire -11.37%
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-14-18 08:00AM  Gritstone Oncology Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals -5.55%
Sep-28-18 09:18AM  Gritstone Oncology expects to begin trading today, prices at $15 per share MarketWatch
07:24AM  [$$] Gritstone Oncology Prices Upsized IPO at Top of Range The Wall Street Journal
Sep-27-18 09:30PM  Gritstone Oncology Announces Pricing of Initial Public Offering GlobeNewswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.